Lineage Cell Therapeutics logo
Lineage Cell Therapeutics LCTX
$ 0.83 -2.45%

Quarterly report 2024-Q2
added 08-08-2024

report update icon

Lineage Cell Therapeutics Deferred Revenue 2011-2024 | LCTX

Annual Deferred Revenue Lineage Cell Therapeutics

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
10.8 M 9.42 M 18.1 M 193 K 45 K 42 K 797 K 572 K 2.95 M 208 K 235 K 401 K 466 K

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
18.1 M 42 K 3.4 M

Quarterly Deferred Revenue Lineage Cell Therapeutics

2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
9.14 M 10.1 M 10.8 M 9.92 M 10.4 M 11 M 9.42 M 12.4 M 15.8 M 14.9 M 18.1 M 975 K 613 K 101 K 193 K 193 K 297 K 193 K 45 K 182 K 45 K 43 K 42 K 42 K 103 K 202 K 309 K 513 K 309 K 309 K 572 K 537 K 572 K 572 K 439 K 439 K 439 K 439 K 208 K 208 K 208 K 208 K 235 K 235 K 235 K 235 K 401 K 401 K 401 K 401 K 204 K 204 K 204 K 204 K

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
18.1 M 42 K 2.68 M